Skip to main content
Skip to main content
Go to homepage

ASP0367 in patients with primary mitochondrial myopathy

Safety and efficacy of ASP0367 in patients with primary mitochondrial myopathy

Description:

See complete study details here.

Interested in participating?
We are currently recruiting
Study Sponsor:

Astellas Pharma, Inc.

Full IRB Study Title:
A Randomized, Double-blind, Placebo-controlled Adaptive Phase 2/3 Study with Open-label Extension to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants with Primary Mitochondrial Myopathy
IRB Study ID:
1713067
If you are interested in this study or have questions about your child's eligibility, please contact:

Hilary Tonni, htonni@akronchildrens.org, 330-543-3193

Lead Investigator
Bruce H. Cohen, MD, FAAN

Director, NeuroDevelopmental Science Center; Interim Vice President and Medical Director, Rebecca D. Considine Research Institute; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center